-
Eating disorders and obesity: bridging clinical, neurobiological, and therapeutic perspectives Trends Mol. Med. (IF 13.6) Pub Date : 2024-03-14 Lucia Camacho-Barcia, Katrin Elisabeth Giel, Susana Jiménez-Murcia, Julio Álvarez Pitti, Nadia Micali, Ignacio Lucas, Romina Miranda-Olivos, Lucero Munguia, Manuel Tena-Sempere, Stephan Zipfel, Fernando Fernández-Aranda
Eating disorders (EDs) and obesity are complex health conditions sharing various risk and maintenance factors, intensified in cases of comorbidity. This review explores the similarities and connections between these conditions, examining different facets from a multidisciplinary perspective, among them comorbidities, metabolic and psychological factors, neurobiological aspects, and management and therapy
-
mRNA vaccine platforms to prevent bacterial infections Trends Mol. Med. (IF 13.6) Pub Date : 2024-03-13 Carson Bergstrom, Nicholas O. Fischer, Jessica Z. Kubicek-Sutherland, Zachary R. Stromberg
Bacterial infections are an urgent public health priority. The application of mRNA vaccine technology to prevent bacterial infections is a promising therapeutic strategy undergoing active development. This article discusses recent advances and limitations of mRNA vaccines to prevent bacterial diseases and provides perspectives on future research directions.
-
iPSC-derived models for anorexia nervosa research Trends Mol. Med. (IF 13.6) Pub Date : 2024-03-12 Gilles Maussion, Cecilia Rocha, Nicolas Ramoz
Anorexia nervosa (AN) is a complex neuropsychiatric disorder with genetic and epigenetic components that results in reduced food intake combined with alterations in the reward-processing network. While studies of patient cohorts and mouse models have uncovered genes and epigenetic changes associated with the disease, neuronal networks and brain areas preferentially activated and metabolic changes associated
-
The body is not just impacted by eating disorders – biology drives them Trends Mol. Med. (IF 13.6) Pub Date : 2024-03-09 James Downs
-
Clinical crusade: zosurabalpin's charge against antibiotic resistance Trends Mol. Med. (IF 13.6) Pub Date : 2024-03-07 Wancai Que, Zixin Deng, Jiangtao Gao
In a recent report, describe a novel tethered macrocyclic peptide (MCP) antibiotic, zosurabalpin, that disrupts the essential function of the LptBFGC complex in Gram-negative bacteria and demonstrates efficacy against carbapenem-resistant (CRAB). Its preclinical success suggests a substantial shift in treating antibiotic resistance, pending clinical trials to validate its effectiveness, pharmacokinetics
-
Epigenetic regulation of tumor-immune symbiosis in glioma Trends Mol. Med. (IF 13.6) Pub Date : 2024-03-07 Yang Liu, Heba Ali, Fatima Khan, Lizhi Pang, Peiwen Chen
Glioma is a type of aggressive and incurable brain tumor. Patients with glioma are highly resistant to all types of therapies, including immunotherapies. Epigenetic reprogramming is a key molecular hallmark in tumors across cancer types, including glioma. Mounting evidence highlights a pivotal role of epigenetic regulation in shaping tumor biology and therapeutic responses through mechanisms involving
-
Unravelling shared mechanisms: insights from recent ME/CFS research to illuminate long COVID pathologies Trends Mol. Med. (IF 13.6) Pub Date : 2024-03-04 Sarah J. Annesley, Daniel Missailidis, Benjamin Heng, Elisha K. Josev, Christopher W. Armstrong
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating chronic illness often triggered by an initiating acute event, mainly viral infections. The transition from acute to chronic disease remains unknown, but interest in this phenomenon has escalated since the COVID-19 pandemic and the post-COVID-19 illness, termed ‘long COVID’ (LC). Both ME/CFS and LC share many clinical similarities
-
Ectodysplasin A2 receptor signaling in skeletal muscle pathophysiology Trends Mol. Med. (IF 13.6) Pub Date : 2024-03-04 Sevgi Döndü Özen, Serkan Kir
Skeletal muscle is essential in generating mechanical force and regulating energy metabolism and body temperature. Pathologies associated with muscle tissue often lead to impaired physical activity and imbalanced metabolism. Recently, ectodysplasin A2 receptor (EDA2R) signaling has been shown to promote muscle loss and glucose intolerance. Upregulated EDA2R expression in muscle tissue was associated
-
Dissecting the biology of feeding and eating disorders Trends Mol. Med. (IF 13.6) Pub Date : 2024-03-01 Laura M. Huckins, Kristen Brennand, Cynthia M. Bulik
Feeding and eating disorders (FEDs) are heterogenous and characterized by varying patterns of dysregulated eating and weight. Genome-wide association studies (GWASs) are clarifying their underlying biology and their genetic relationship to other psychiatric and metabolic/anthropometric traits. Genetic research on anorexia nervosa (AN) has identified eight significant loci and uncovered genetic correlations
-
HDL and SARS CoV-2: emerging theragnostic implications Trends Mol. Med. (IF 13.6) Pub Date : 2024-03-01 Alankrita Rani, Julia T. Stadler, Gunther Marsche
High-density lipoproteins (HDLs) are complex particles with multiple functions. They are thought to have evolved as part of the body’s innate defense system against infection. Recent research suggests that HDL levels influence susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the severity of associated complications, making it a promising target for therapeutic
-
HDAC inhibitors as pharmacological treatment for Duchenne muscular dystrophy: a discovery journey from bench to patients Trends Mol. Med. (IF 13.6) Pub Date : 2024-02-26 Chiara Mozzetta, Vittorio Sartorelli, Christian Steinkuhler, Pier Lorenzo Puri
Earlier evidence that targeting the balance between histone acetyltransferases (HATs) and deacetylases (HDACs), through exposure to HDAC inhibitors (HDACis), could enhance skeletal myogenesis, prompted interest in using HDACis to promote muscle regeneration. Further identification of constitutive HDAC activation in dystrophin-deficient muscles, caused by dysregulated nitric oxide (NO) signaling, provided
-
Science around the world Trends Mol. Med. (IF 13.6) Pub Date : 2024-02-23 Jeremy P. Burton, Rikke Hahn Kofoed, Ruslan Rust
-
There is nothing as inconsistent as the OSFED diagnostic criteria Trends Mol. Med. (IF 13.6) Pub Date : 2024-02-22 Isabel Krug, An Binh Dang, Elizabeth K. Hughes
Atypical anorexia nervosa (AAN), purging disorder (PD), night eating syndrome (NES), and subthreshold bulimia nervosa and binge-eating disorder (Sub-BN/BED) are the five categories that comprise the ‘Other Specified Feeding or Eating Disorder’ (OSFED) category in the (). In this review, we examine problems with the diagnostic criteria that are currently proposed for the five OSFED types. We conclude
-
-
-
Anorexia nervosa: diagnostic, therapeutic, and risk biomarkers in clinical practice Trends Mol. Med. (IF 13.6) Pub Date : 2024-02-08 Hubertus Himmerich, Janet Treasure
In anorexia nervosa (AN), measurable biological parameters can inform the process of treating patients. Such biomarkers include established laboratory parameters as well as a range of potential future biomarkers, including genetic, metabolomic, microbiomic, endocrine, immunological, hematological, electrophysiological, and neuroimaging parameters. In this opinion article we discuss how these biomarkers
-
Hyaluronan deposition during COVID-19 – helpful or harmful? Trends Mol. Med. (IF 13.6) Pub Date : 2024-02-07 Duncan Hart, William A. Petri
Hyaluronan (HA), an extracellular matrix polysaccharide, is increased in the lungs during COVID-19 and correlates with severity. HA acts as an immune mediator that aids cell trafficking and intracellular signaling, but its role in COVID-19 is debated. Although HA is implicated in pulmonary viral disease pathogenesis, some studies suggest a potential protective function in COVID-19.
-
Immune cell-derived signals governing epithelial phenotypes in homeostasis and inflammation Trends Mol. Med. (IF 13.6) Pub Date : 2024-02-05 Annika Hausmann, Casper Steenholdt, Ole H. Nielsen, Kim B. Jensen
The intestinal epithelium fulfills important physiological functions and forms a physical barrier to the intestinal lumen. Barrier function is regulated by several pathways, and its impairment contributes to the pathogenesis of inflammatory bowel disease (IBD), a chronic inflammatory condition affecting more than seven million people worldwide. Current treatment options specifically target inflammatory
-
Organ-specific aging in the plasma proteome predicts disease Trends Mol. Med. (IF 13.6) Pub Date : 2024-01-31 Michael R. Duggan, Keenan A. Walker
In their recent Nature paper, Oh et al. use 4979 plasma proteins collected across multiple cohorts, publicly available gene expression data, and machine learning models to identify 11 organ-specific aging scores that are linked to organ-specific disease and mortality risk, including heart failure, cognitive decline, and Alzheimer’s disease.
-
TIM-3 inhibitors: a promising strategy for tumor immunotherapy Trends Mol. Med. (IF 13.6) Pub Date : 2024-01-31 Lu Lu, Liufu Deng
recently reported a systematic screening of small-molecule compounds targeting the FG-CC' cleft of T cell immunoglobulin and mucin-containing molecule 3 (TIM-3). They identified a functional Tim-3 inhibitor, ML-T7, that, as a single agent or in combination with anti-PD-1, demonstrated strong antitumor activity in preclinical mouse tumor models, supporting its potential for further clinical translation
-
Resistance exercise for anxiety and depression: efficacy and plausible mechanisms Trends Mol. Med. (IF 13.6) Pub Date : 2024-01-30 Matthew P. Herring, Jacob D. Meyer
Anxiety and depressive symptoms and disorders are prevalent and poorly treated. The salutary benefits of resistance exercise training (RET), a potential alternative therapy, are well established, but mental health effects are understudied. This forum article summarizes the most rigorous evidence regarding efficacy of resistance exercise and provides a primer for putative psychobiological mechanisms
-
Science around the world Trends Mol. Med. (IF 13.6) Pub Date : 2024-01-25 Pedro Antas, Abigail Cleveland, Paolo Contessotto, Raffael Schaffrath
Abstract not available
-
Omaveloxolone: a groundbreaking milestone as the first FDA-approved drug for Friedreich ataxia Trends Mol. Med. (IF 13.6) Pub Date : 2024-01-24 Federica Pilotto, Deepika M. Chellapandi, Hélène Puccio
Friedreich ataxia (FA) is an inherited autosomal recessive neurodegenerative disease (NDD) characterized primarily by progressive sensory and spinocerebellar ataxia associated with hypertrophic cardiomyopathy. FA is due to an intronic GAA repeat expansion within the frataxin gene (FXN) leading to reduced levels of frataxin (FXN) which causes mitochondrial dysfunction, production of reactive oxygen
-
Beneath the radar: immune-evasive cell sources for stroke therapy Trends Mol. Med. (IF 13.6) Pub Date : 2024-01-25 Beatriz Achón Buil, Nora H. Rentsch, Rebecca Z. Weber, Chiara Rickenbach, Stefanie J. Halliday, Akitsu Hotta, Christian Tackenberg, Ruslan Rust
Stem cell therapy is an emerging treatment paradigm for stroke patients with remaining neurological deficits. While allogeneic cell transplants overcome the manufacturing constraints of autologous grafts, they can be rejected by the recipient’s immune system, which identifies foreign cells through the human leukocyte antigen (HLA) system. The heterogeneity of HLA molecules in the human population would
-
Focused ultrasound gene delivery for the treatment of neurological disorders Trends Mol. Med. (IF 13.6) Pub Date : 2024-01-11 Rikke Hahn Kofoed, Isabelle Aubert
The transformative potential of gene therapy has been demonstrated in humans. However, there is an unmet need for non-invasive targeted gene delivery and regulation in the treatment of brain disorders. Transcranial focused ultrasound (FUS) has gained tremendous momentum to address these challenges. FUS non-invasively modulates brain cells and their environment, and is a powerful tool to facilitate
-
The sense of antisense therapies in ALS Trends Mol. Med. (IF 13.6) Pub Date : 2024-01-11 Sien H. Van Daele, Pegah Masrori, Philip Van Damme, Ludo Van Den Bosch
Treatment of patients with amyotrophic lateral sclerosis (ALS) has entered a new era now that encouraging results about antisense oligonucleotides (ASOs) are becoming available and a first ASO therapy for ALS has been approved by the FDA. Moreover, there is hope not only that ALS can be stopped but also that symptoms can be reversed. Until now, degrading ASOs seemed to be successful mostly for rarer
-
-
Let science take you around the world Trends Mol. Med. (IF 13.6) Pub Date : 2024-01-10 Aliki Perdikari
Abstract not available
-
Science around the world Trends Mol. Med. (IF 13.6) Pub Date : 2024-01-10 Navika Gangrade, Cecilia Hidalgo, Thirumala-Devi Kanneganti, Gwendal Lazennec
Abstract not available
-
Subscription and Copyright Information Trends Mol. Med. (IF 13.6) Pub Date : 2024-01-10
Abstract not available
-
Dissecting mechanisms of fecal microbiota transplantation efficacy in disease Trends Mol. Med. (IF 13.6) Pub Date : 2024-01-08 Catherine M. Andary, Kait F. Al, John A. Chmiel, Shaeley Gibbons, Brendan A. Daisley, Seema Nair Parvathy, Saman Maleki Vareki, Dawn M.E. Bowdish, Michael S. Silverman, Jeremy P. Burton
Fecal microbiota transplantation (FMT) has emerged as an alternative or adjunct experimental therapy for microbiome-associated diseases following its success in the treatment of recurrent infections (rCDIs). However, the mechanisms of action involved remain relatively unknown. The term ‘dysbiosis’ has been used to describe microbial imbalances in relation to disease, but this traditional definition
-
Immune system perturbations in patients with long COVID Trends Mol. Med. (IF 13.6) Pub Date : 2024-01-04 Lucie Rodriguez, Petter Brodin
report multimodal analyses of immune cells, proteins, and physiological parameters in patients with long COVID (LC). At the group level, LC subjects exhibited elevated antibody responses to SARS-CoV-2, but also to herpes viruses, pointing to a general suppression of viral control mechanisms in LC.
-
Glycosylation of blood cells during the onset and progression of atherosclerosis and myocardial infarction Trends Mol. Med. (IF 13.6) Pub Date : 2023-12-22 Federico Ferro, Renza Spelat, Abhay Pandit, José L. Martin-Ventura, Gabriel A. Rabinovich, Paolo Contessotto
Protein glycosylation controls cell–cell and cell–extracellular matrix (ECM) communication in immune, vascular, and inflammatory processes, underlining the critical role of this process in the identification of disease biomarkers and the design of novel therapies. Emerging evidence highlights the critical role of blood cell glycosylation in the pathophysiology of atherosclerosis (ATH) and myocardial
-
From disparities to equity: striving for more in our treatments for feeding and eating disorders Trends Mol. Med. (IF 13.6) Pub Date : 2023-12-21 Rachel W. Goode, Salomé Adelia Wilfred, Mae Lynn Reyes-Rodríguez
Adopting a framework of equity is urgently needed to reduce disparities persistent in feeding and eating disorder (FED) treatment models. This framework must emphasize the exchange of knowledge between relevant stakeholders and implementation strategies to impact practice and embrace a systemic change in the FED field.
-
Endocrinology-informed neuroimaging in eating disorders: GLP1, orexins, and psilocybin Trends Mol. Med. (IF 13.6) Pub Date : 2023-12-19 Trevor Steward
The neurobiology of eating disorders [EDs; anorexia nervosa (AN), bulimia nervosa (BN), and binge eating disorder (BED)] remains poorly understood. Here, I describe how neuroimaging, accompanied by peripheral endocrine measures, can provide insights into the neurobiological drivers of eating disorders. Orexins/hypocretins, glucagon-like peptide-1 receptor (GLP1R) agonists, and psilocybin are highlighted
-
FBXL4 mutation-caused mitochondrial DNA depletion syndrome is driven by BNIP3/BNIP3L-dependent excessive mitophagy Trends Mol. Med. (IF 13.6) Pub Date : 2023-12-19 Kun Gao, Xiayun Xu, Chenji Wang
Encephalomyopathic mitochondrial DNA (mtDNA) depletion syndrome 13 (MTDPS13) is an autosomal recessive disorder arising from biallelic F-box and leucine-rich repeat (LRR) protein 4 (FBXL4) gene mutations. Recent advances have shown that excessive BCL2 interacting protein 3 (BNIP3)/ BCL2 interacting protein 3 like (BNIP3L)-dependent mitophagy underlies the molecular pathogenesis of MTDPS13. Here, we
-
Taking better advantage of the activity-based anorexia model Trends Mol. Med. (IF 13.6) Pub Date : 2023-12-15 Claire J. Foldi
The lack of specific treatments for anorexia nervosa (AN) is partly driven by an inadequate understanding of the neurobiological drivers of the condition. The activity-based anorexia (ABA) model recapitulates key characteristics of AN in rats and mice, and can be used to understand factors that predispose, maintain, and rescue anorectic behaviour. With the rapidly evolving suite of technologies to
-
Diphthamide – a conserved modification of eEF2 with clinical relevance Trends Mol. Med. (IF 13.6) Pub Date : 2023-12-13 Raffael Schaffrath, Ulrich Brinkmann
Diphthamide, a complex modification on eukaryotic translation elongation factor 2 (eEF2), assures reading-frame fidelity during translation. Diphthamide and enzymes for its synthesis are conserved in eukaryotes and archaea. Originally identified as target for diphtheria toxin (DT) in humans, its clinical relevance now proves to be broader than the link to pathogenic bacteria. Diphthamide synthesis
-
TIM-3 blockade: immune and targeted therapy in DIPG Trends Mol. Med. (IF 13.6) Pub Date : 2023-12-12 Yan Hu, Peishan Hu, Xiaozhong Peng
Diffuse intrinsic pontine glioma (DIPG) remains intractable to conventional treatments. While targeted therapy and immuno-oncology advances offer hope, few strategies show promising results. In a recent article in Cancer Cell, Ausejo-Mauleon et al. introduce TIM-3 blockade as a potential breakthrough for DIPG treatment by targeting cancer cells and regulating the immune microenvironment simultaneously
-
Role of intrinsic apoptosis in environmental exposure health outcomes Trends Mol. Med. (IF 13.6) Pub Date : 2023-12-05 Lissah Johnson, Kristopher A. Sarosiek
Environmental exposures are linked to diseases of high public health concern, including cancer, neurodegenerative disorders, and autoimmunity. These diseases are caused by excessive or insufficient cell death, prompting investigation of mechanistic links between environmental toxicants and dysregulation of cell death pathways, including apoptosis. This review describes how legacy and emerging environmental
-
Toward low-cost gene therapy: mRNA-based therapeutics for treatment of inherited retinal diseases Trends Mol. Med. (IF 13.6) Pub Date : 2023-12-02 Pedro Antas, Cláudia Carvalho, Joaquim Cabral-Teixeira, Luísa de Lemos, Miguel C. Seabra
Inherited retinal diseases (IRDs) stem from genetic mutations that result in vision impairment. Gene therapy shows promising therapeutic potential, exemplified by the encouraging initial results with voretigene neparvovec. Nevertheless, the associated costs impede widespread access, particularly in low-to-middle income countries. The primary challenge remains: how can we make these therapies globally
-
Eating disorders: are gut microbiota to blame? Trends Mol. Med. (IF 13.6) Pub Date : 2023-11-30 Jiayi Xu, Ian M. Carroll, Laura M. Huckins
Gut microbiota could be involved in weight regulation and impact brain function via the gut–brain axis. Moreover, gut microbiota may impact the development of eating disorders (EDs) since they are characterized by weight-related concerns and symptoms and may represent a therapeutic target if future research can establish a causal link.
-
Reprogramming endothelial cells to empower cancer immunotherapy Trends Mol. Med. (IF 13.6) Pub Date : 2023-11-30 Abigail H. Cleveland, Yi Fan
Cancer immunity is subject to spatiotemporal regulation by leukocyte interaction with the tumor microenvironment. Growing evidence suggests an emerging role for the vasculature in tumor immune evasion and immunotherapy resistance. Beyond the conventional functions of the tumor vasculature, such as providing oxygen and nutrients to support tumor progression, we propose multiplex mechanisms for vascular
-
Redefining metalloproteases specificity through network proteolysis Trends Mol. Med. (IF 13.6) Pub Date : 2023-11-29 Orit Kollet, Alakesh Das, Nikos Karamanos, Ulrich auf dem Keller, Irit Sagi
Proteolytic processes on cell surfaces and extracellular matrix (ECM) sustain cell behavior and tissue integrity in health and disease. Matrix metalloproteases (MMPs) and a disintegrin and metalloproteases (ADAMs) remodel cell microenvironments through irreversible proteolysis of ECM proteins and cell surface bioactive molecules. Pan-MMP inhibitors in inflammation and cancer clinical trials have encountered
-
The ignored role of disadvantage in eating disorders Trends Mol. Med. (IF 13.6) Pub Date : 2023-11-24 C. Blair Burnette, S. Alexandra Burt, Kelly L. Klump
The misconception that eating disorders are conditions of affluence has shaped research and public understanding for decades. Here, we highlight links between socioeconomic disadvantage and eating disorder risk. With prevailing stereotypes discredited, we argue that considering disadvantage as a key eating disorder risk factor will advance science and reduce disparities.
-
Digital health applications for eating disorders treatment Trends Mol. Med. (IF 13.6) Pub Date : 2023-11-22 Matthew Fuller-Tyszkiewicz, Mariel Messer, Isabel Krug, Jake Linardon
Eating disorders (EDs) are characterized by multifaceted etiologies, difficulties in accessing care (especially in regional locations), and variable responsiveness to treatments. Digital technologies are viewed as an important innovation in the assessment and treatment of EDs. We discuss current implementation of these innovations as well as important future directions for the field.
-
Embodiment illusions and eating disorders: snapshot of implications for research and interventions Trends Mol. Med. (IF 13.6) Pub Date : 2023-11-17 Jade Portingale, Isabel Krug, David Butler
In recent years, researchers have increasingly used the embodiment illusion paradigm in subclinical and clinical eating disorder (ED) populations. This has important implications for understanding and ultimately improving bodily misperception. Here, we provide a brief overview of the current 'state of the art' of these implications while highlighting challenges and future directions.
-
Therapeutic potential of PANoptosis: innate sensors, inflammasomes, and RIPKs in PANoptosomes Trends Mol. Med. (IF 13.6) Pub Date : 2023-11-15 Ankit Pandeya, Thirumala-Devi Kanneganti
The innate immune system initiates cell death pathways in response to pathogens and cellular stress. Cell death can be either non-lytic (apoptosis) or lytic (PANoptosis, pyroptosis, and necroptosis). PANoptosis has been identified as an inflammatory, lytic cell death pathway driven by caspases and RIPKs that is regulated by PANoptosome complexes, making it distinct from other cell death pathways. Several
-
RyR-mediated calcium release in hippocampal health and disease Trends Mol. Med. (IF 13.6) Pub Date : 2023-11-11 Cecilia Hidalgo, Andrea Paula-Lima
Hippocampal synaptic plasticity is widely considered the cellular basis of learning and spatial memory processes. This article highlights the central role of Ca2+ release from the endoplasmic reticulum (ER) in hippocampal synaptic plasticity and hippocampus-dependent memory in health and disease. The key participation of ryanodine receptor (RyR) channels, which are the principal Ca2+ release channels
-
-
Three ‘E’ challenges for siRNA drug development Trends Mol. Med. (IF 13.6) Pub Date : 2023-11-09 Shuai Guo, Mengjie Zhang, Yuanyu Huang
siRNA therapeutics have gained extensive attention, and to date six siRNAs are approved for clinical use. Despite being investigated for the treatment of metabolic, cardiovascular, infectious, and rare genetic diseases, cancer, and central nervous system (CNS) disorders, there exist several druggability challenges. Here, we provide insightful discussions concerning these challenges, comprising targeted
-
Subscription and Copyright Information Trends Mol. Med. (IF 13.6) Pub Date : 2023-11-08
Abstract not available
-
Disease association and therapeutic routes of aminoacyl-tRNA synthetases Trends Mol. Med. (IF 13.6) Pub Date : 2023-11-08 Ina Yoon, Uijoo Kim, Jaeyoung Choi, Sunghoon Kim
Aminoacyl-tRNA synthetases (ARSs) are enzymes that catalyze the ligation of amino acids to tRNAs for translation. Beyond their traditional role in translation, ARSs have acquired regulatory functions in various biological processes (epi-translational functions). With their dual-edged activities, aberrant expression, secretion, and mutations of ARSs are associated with human diseases, including cancer
-
Youth-associated platelet-derived chemokine reverses brain aging through neuroimmune mechanisms Trends Mol. Med. (IF 13.6) Pub Date : 2023-11-07 Brittany M. Hemmer, Sarah M. Philippi, Joseph M. Castellano
Age-related loss of brain function has been seen as inevitable, yet recent work leveraging the systemic environment challenges this notion. Schroer et al. demonstrate that youth-associated platelet factor 4 (PF4) partially restores brain function in aged mice while reducing peripheral immune dysfunction, supporting periphery-based approaches to treat age-associated brain disorders.
-
Postdoctoral mentorship needs a reform Trends Mol. Med. (IF 13.6) Pub Date : 2023-11-01 Navika Gangrade, W. Marcus Lambert
To retain talented scientists in academia, there is a need for structural reform to postdoctoral researcher (postdoc) mentorship. These changes include mentorship training for postdocs and their mentors, formalizing postdoc mentorship networks and postdoc cohorts within a department, and incorporating mentorship development plans (MDPs) in funding decisions for principal investigators (PIs).
-
Time-restricted feeding and Alzheimer’s disease: you are when you eat Trends Mol. Med. (IF 13.6) Pub Date : 2023-10-21 Melvin W. King, Yining Chen, Erik S. Musiek
Time-restricted feeding (TRF) has emerged as a means of synchronizing circadian rhythms, which are commonly disrupted in Alzheimer’s disease (AD). Whittaker et al. demonstrate that TRF exerts protective effects in two mouse models of AD. We discuss the effects of TRF on brain health and mechanisms linking TRF to neurodegeneration.
-
CXCR2 chemokine receptor – a master regulator in cancer and physiology Trends Mol. Med. (IF 13.6) Pub Date : 2023-10-21 Gwendal Lazennec, Krishna Rajarathnam, Ann Richmond
Recent findings have modified our understanding of the roles of chemokine receptor CXCR2 and its ligands in cancer, inflammation, and immunity. Studies in Cxcr2 tissue-specific knockout mice show that this receptor is involved in, among other things, cancer, central nervous system (CNS) function, metabolism, reproduction, COVID-19, and the response to circadian cycles. Moreover, CXCR2 involvement in
-
Hyperthermia–embolization–immunotherapy: a potent trio in advancing cancer treatment Trends Mol. Med. (IF 13.6) Pub Date : 2023-10-18 Rahela Zaman, Xiaojun Cai, Quazi T.H. Shubhra
Yang et al. recently demonstrated the high potential of liquid metal microspheres (LM MSs) in cancer therapy. By amplifying the effects of magnetic hyperthermia and embolization, LM MSs not only target primary tumors, but also potentiate immune defenses. This dual-action approach effectively curtails distant tumor growth, marking a pivotal advancement in cancer immunotherapy.
-
-
Subscription and Copyright Information Trends Mol. Med. (IF 13.6) Pub Date : 2023-10-11
Abstract not available